Investment
Features
FeesSafety
Academy
More
Pluang+

BNP Paribas reports unchanged voting rights and share count as of June 30, 2026.

Company Fundamentals
06 Jul 2026
Globe News Wire
View Source
Neutral
pluang ai news

BNP Paribas announced its monthly declaration of voting rights and share capital as of June 30, 2026. The bank's total number of shares and voting rights both stand at 1,101,600,607, indicating no changes from previous reports. This regular disclosure complies with French commercial and financial market regulations, providing transparency to investors about the company's capital structure. No additional events or changes were reported in this update.

More News

Reactive hot melt adhesives market to reach $4.29B by 2035, driven by automotive and furniture demand.

Reactive hot melt adhesives market to reach $4.29B by 2035, driven by automotive and furniture demand.

The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...

Market News
Bullish
38 minutes ago
Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...

Market News
Bullish
4 hours ago
CHARBONE expands helium fleet amid global shortages, boosting North American supply and customer base.

CHARBONE expands helium fleet amid global shortages, boosting North American supply and customer base.

CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...

Market News
Bullish
4 hours ago
Citi initiates buy on Hikma Pharmaceuticals with a £17 target, citing strategic reset and growth potential.

Citi initiates buy on Hikma Pharmaceuticals with a £17 target, citing strategic reset and growth potential.

Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...

Analyst Insights
Bullish
4 hours ago
Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.

Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.

Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App